Shi Hongxing, Lan Limin, Lv Xianghong, Sun Lizhi
Department of Pediatrics, Zhangqiu District Maternal and Child Health Care Hospital, Jinan, Shandong 250200, P.R. China.
Department of Pharmacy, Yantaishan Hospital, Yantai, Shandong 264000, P.R. China.
Exp Ther Med. 2019 Sep;18(3):1800-1806. doi: 10.3892/etm.2019.7725. Epub 2019 Jul 3.
This study explored the effect of pidotimod combined with azithromycin on children with mycoplasma pneumonia and the expression of interleukin-10 (IL-10) and granulocyte colony-stimulating factor (G-CSF) in serum. The clinical data of 149 children with mycoplasma pneumonia from May 2014 to May 2018 in Zhangqiu District Maternal and Child Health Care Hospital were collected. Among them, 70 children treated with azithromycin sequential therapy were the control group, and 79 children treated with the combination of pidotimod and azithromycin were the observation group. Double antibody sandwich enzyme-linked immunosorbent assay (ELISA) was used to determine the expression levels of IL-10 and G-CSF in serum before and after treatment. Pearson's correlation coefficient was used to analyze the correlation between IL-10 and G-CSF in serum. The total effective rate in the observation group (94.94%) was significantly higher than that in the control group (81.43%) (P<0.05). There was no significant difference in the expression levels of IL-10 and G-CSF between the two groups before treatment (P>0.05). The expression levels of IL-10 and G-CSF in the two groups after treatment were significantly lower than those before treatment (P<0.05). After treatment, the expression levels of IL-10 and G-CSF in serum in the observation group were significantly lower than those in the control group. There was a significant positive correlation between the expression levels of IL-10 and G-CSF before and after treatment in the observation group (P<0.05), and a significant positive correlation between the expression levels of IL-10 and G-CSF before and after treatment in the control group (P<0.05). Compared with sequential treatment with azithromycin alone, pidotimod combined with azithromycin significantly reduced the expression levels of IL-10 and G-CSF in serum of children with mycoplasma pneumonia, improved the curative effect and reduced the occurrence of adverse reactions, which has high application value in clinic.
本研究探讨匹多莫德联合阿奇霉素对支原体肺炎患儿的影响及血清白细胞介素 -10(IL -10)和粒细胞集落刺激因子(G -CSF)的表达。收集了章丘区妇幼保健院2014年5月至2018年5月期间149例支原体肺炎患儿的临床资料。其中,70例接受阿奇霉素序贯治疗的患儿为对照组,79例接受匹多莫德联合阿奇霉素治疗的患儿为观察组。采用双抗体夹心酶联免疫吸附测定法(ELISA)检测治疗前后血清中IL -10和G -CSF的表达水平。采用Pearson相关系数分析血清中IL -10与G -CSF的相关性。观察组总有效率(94.94%)显著高于对照组(81.43%)(P<0.05)。治疗前两组IL -10和G -CSF表达水平差异无统计学意义(P>0.05)。两组治疗后IL -10和G -CSF表达水平均显著低于治疗前(P<0.05)。治疗后,观察组血清中IL -10和G -CSF表达水平显著低于对照组。观察组治疗前后IL -10和G -CSF表达水平呈显著正相关(P<0.05),对照组治疗前后IL -10和G -CSF表达水平也呈显著正相关(P<0.05)。与单纯阿奇霉素序贯治疗相比,匹多莫德联合阿奇霉素显著降低了支原体肺炎患儿血清中IL -10和G -CSF的表达水平,提高了疗效,减少了不良反应的发生,在临床上具有较高的应用价值。